RPS6KB1 and acute myeloid leukemia: In acute myeloid leukemia (AML), activating mutations in RTKs such as FLT3 or c-Kit drive sustained PAM signaling, confirmed by hyperphosphorylation of mTORC1 substrates S6K and 4E-BP1 in primary AML samples [148,149].